Analysts at Jefferies International Maintain their Past ‘Buy’ rating on Shares AstraZeneca PLC (LON:AZN), Set a GBX 5300.00 Target Price


AstraZeneca PLC (LON:AZN) Rating Reaffirmed

Research professionals at Jefferies International now has a GBX 5300.00 target price on AstraZeneca PLC (LON:AZN). Jefferies International and their recent target price would indicate a potential upside of 19.67% from the company’s previous stock close. The rating has been unveiled in a recent report on 7 December.

From a total of 29 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 94.17 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 70.59 with a 9.21% above today’s (GBX 4428.92) stock price. AstraZeneca PLC was the topic of 118 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Handelsbanken maintained shares on December 4 with “Accumulate” rating. Credit Suisse maintained shares with “Underperform” rating and GBX 4000 target share price in a report from a November 24. Bernstein maintained AZN stock in a recent report from December 1 with “Market Perform” rating. Goldman Sachs maintained the rating on November 24. Goldman Sachs has a “Neutral” rating and a GBX 4300 price target on shares. Finally, UBS maintained the stock with “Buy” rating in a report issued on a November 25.

The stock decreased 0.92% or GBX 41.08 on December 4, striking GBX 4428.92. Approximately shares of stock traded hands. AstraZeneca plc (LON:AZN) has declined 1.99% since May 8, 2015 and is downtrending. It has underperformed by 0.91% the S&P500.

Analysts at Jefferies International Maintain their Past ‘Buy’ rating on Shares AstraZeneca PLC (LON:AZN), Set a GBX 5300.00 Target Price

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 56.14 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.05 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.” Get a free copy of the Zacks research report on AstraZeneca plc (AZN).